Abstract
This article focuses on the management of locally advanced pancreatic cancer, which should be treated as a distinct entity separate from metastatic disease and borderline resectable disease. Although the role, timing, and sequencing of radiation relative to systemic therapy in this disease are controversial, an emerging treatment paradigm involves induction chemotherapy, followed by consolidative chemoradiation in patients who do not progress. In addition, new chemotherapy regimens as well as novel radiosensitizers have shown promise and need to be tested further in the locally advanced setting. Advances in radiotherapy have enabled stereotactic body radiotherapy and should continue to be prospectively evaluated.
Original language | English (US) |
---|---|
Pages (from-to) | 741-759 |
Number of pages | 19 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 29 |
Issue number | 4 |
DOIs | |
State | Published - Aug 1 2015 |
Keywords
- Combined-modality therapy
- Induction
- Locally advanced
- Pancreatic cancer
- Stereotactic body radiation
ASJC Scopus subject areas
- Oncology
- Hematology
- General Medicine